Mereo BioPharma (MREO) Intangibles (2017 - 2026)

Mereo BioPharma (MREO) has reported Intangibles for 10 consecutive years, with $381000.0 the latest figure, recorded in Q1 2026.

• Quarterly Intangibles fell 31.23% year-over-year to $381000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $381000.0 (down 31.23% YoY) and the FY2025 annual result came in at $516000.0, down 19.75% from the prior year.
• Intangibles slipped to $381000.0 in Q1 2026 per MREO's latest filing, from $516000.0 in the prior quarter.
• Over the last five years, Intangibles for MREO reached as high as $31.1 million in Q2 2023 and fell as low as $381000.0 in Q1 2026.
• A 5-year average of $7.4 million and a median of $799000.0 in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2023 — Intangibles rose 2.37% — and 2024, when it plunged 97.21%.
• Year by year, Intangibles stood at $28.3 million in 2022, then plunged by 96.15% to $1.1 million in 2023, then tumbled by 40.96% to $643000.0 in 2024, then decreased by 19.75% to $516000.0 in 2025, then dropped by 26.16% to $381000.0 in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $381000.0, $516000.0, and $643000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.